Table 3.
Baseline characteristics of the study 2 sample (n=49)
Characteristic | Descriptive statistic |
---|---|
Sex (% female) | 67.3 |
Race (%) | |
White | 61.2 |
African-American | 26.5 |
Asian | 6.1 |
Ethnicity (% non-Hispanic) | 97.9 |
Age (MN±SD) | 39.7±9.96 |
CLBP duration (median, in months) | 78.7 |
Worst pain past 24 hours (mean±SD) | 6.0±2.36 |
Average pain past 24 hours (mean±SD) | 4.6±2.49 |
Best pain past 24 hours (mean±SD) | 3.1±2.59 |
PROMIS pain interference 8a (mean±SD) | 23.7±9.12 |
Medications (%) | |
As-needed opioids | 14.3 |
Antidepressants | 49.0 |
Neuroleptics | 38.7 |
As-needed NSAIDs | 42.9 |
HOME: opioid exposure (mean±SD) | 2.2±1.54 |
HOME: euphoric response (mean±SD) | 3.2±1.25 |
CLBP, chronic low back pain; HOME, History of Opioid Medical Exposure; NSAID, non-steroidal anti-inflammatory drug; PROMIS, Patient-Reported Outcomes Measurement Information System.